[Extended metabolic diagnosis of urolithiasis].
OBJECTIVE
In Germany, urolithiasis, with a frequency of 5 % and a continuously increasing incidence, must be considered as a widespread disease. Ever growing socio-economic expenses have become the focus of attention. The present treatment strategies provide only limited support for the practitioner in evaluating the often complex causes of urolithiasis and in assessing the chosen treatment. A successful treatment with minimal effort requires a general improvement of existing options in prophylaxis as well as metaphylaxis of urolithiasis. For this purpose, detailed examination and interpretation of a stone-former's urinary composition are essential.


METHODS
The following two novel and significant methods with rapid and uncomplicated application procedures are presented: 1) The easy-to-perform and accurate determination of the calcium oxalate crystallisation risk from a urine sample using the BONN risk index (BRI) for the most frequently occurring stone type (75 %). 2) Consideration of the chemical depletion of lithogenic components in a urine sample due to in-vivo growing uroliths. This phenomenon, the so-called depletion effect, can be of considerable clinical relevance due to possible determination of false normal urinary parameters.


RESULTS
This review article explains the theoretical background of these methods and the many applications of the novel methods in practice.


CONCLUSIONS
New strategies in stone prevention can help to reduce the extent of urolithiasis in a patient. The BRI enables the practitioner to optimise patient treatment without major effort. Consideration of the stone growth-related alteration of composition improves the interpretation of urine analysis.
Laube
N
N
Universitätsklinikum Bonn, Klinik und Poliklinik für Urologie.
Bradenahl
J
J
Thomas
E
E
Meissner
A
A
Müller
S C
SC
D002129:Calcium Oxalate / Q000652:urine*; D003460:Crystallization; D006801:Humans; D011237:Predictive Value of Tests; D012307:Risk Factors; D014545:Urinary Calculi / Q000517:prevention & control / Q000652:urine*
D002129:Calcium Oxalate